Anti-CD30 CAR-T cell therapy (National Cancer Institute)

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameAnti-CD30 CAR-T cell therapy (National Cancer Institute)
Drug Alias NameHu30-CD28z
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy
Mechanisms of ActionTumor necrosis factor receptor superfamily member 8 inhibitors
TargetsTumor necrosis factor receptor superfamily member 8
Therapy Area/IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, Extranodal NK-T-Cell +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesNational Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsLymphoma, T-Cell, PeripheralLymphoma, Large-Cell, AnaplasticLymphoma, Extranodal NK-T-Cell +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A